Quality by Design: Industrial Case Studies on Defining and Implementing Design Space for Pharmaceutical Processes—Part 1 - How to use multivariate experiments to define acceptable ranges. - BioP

ADVERTISEMENT

Quality by Design: Industrial Case Studies on Defining and Implementing Design Space for Pharmaceutical Processes—Part 1
How to use multivariate experiments to define acceptable ranges.


BioPharm International
Volume 21, Issue 12

PROCESS CHARACTERIZATION


Figure 2a. The key steps in process characterization. First, a risk analysis is performed, often using the failure modes and effects analysis (FMEA) method, to identify parameters for process characterization. Second, studies are designed using design of experiments (DOE). Third, the studies are executed and the results are analyzed to make decisions about the criticality of the parameters and to establish the design space.
As shown in Figures 2a and 2b, once acceptable critical quality attributes have been established, process characterization studies can be used to define the acceptable range of process parameters. Operating within these acceptable ranges—the interaction of which will ultimately define the design space—ensures quality. Those acceptable ranges are documented in the regulatory filing.


Figure 2b. Illustration of the design space and its relationship to the characterized and operating ranges. The operating range denotes the range in manufacturing procedures; the characterization range is the range examined during process characterization; and the acceptable range (AR) is the output of the characterization studies. The AR defines the design space and is documented in the regulatory filing. Adapted from reference 7.
The overall approach to process characterization involves three key steps.6,8 First, a risk analysis is performed to identify parameters for process characterization. Second, studies are designed using design of experiments (DOE) so that the resulting data will be amenable for use in understanding and defining the design space. Third, the studies are executed and the results analyzed for decisions about the criticality of the parameters and about establishing the design space.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International,
Click here